168 related articles for article (PubMed ID: 31302002)
1. IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer.
Colomer C; Margalef P; Villanueva A; Vert A; Pecharroman I; Solé L; González-Farré M; Alonso J; Montagut C; Martinez-Iniesta M; Bertran J; Borràs E; Iglesias M; Sabidó E; Bigas A; Boulton SJ; Espinosa L
Mol Cell; 2019 Aug; 75(4):669-682.e5. PubMed ID: 31302002
[TBL] [Abstract][Full Text] [Related]
2. BRAF-induced tumorigenesis is IKKα-dependent but NF-κB-independent.
Margalef P; Colomer C; Villanueva A; Montagut C; Iglesias M; Bellosillo B; Salazar R; Martínez-Iniesta M; Bigas A; Espinosa L
Sci Signal; 2015 Apr; 8(373):ra38. PubMed ID: 25900832
[TBL] [Abstract][Full Text] [Related]
3. A truncated form of IKKα is responsible for specific nuclear IKK activity in colorectal cancer.
Margalef P; Fernández-Majada V; Villanueva A; Garcia-Carbonell R; Iglesias M; López L; Martínez-Iniesta M; Villà-Freixa J; Mulero MC; Andreu M; Torres F; Mayo MW; Bigas A; Espinosa L
Cell Rep; 2012 Oct; 2(4):840-54. PubMed ID: 23041317
[TBL] [Abstract][Full Text] [Related]
4. DNA-dependent protein kinase modulates the anti-cancer properties of silver nanoparticles in human cancer cells.
Lim HK; Gurung RL; Hande MP
Mutat Res Genet Toxicol Environ Mutagen; 2017 Dec; 824():32-41. PubMed ID: 29150048
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ATR-dependent signaling by protoapigenone and its derivative sensitizes cancer cells to interstrand cross-link-generating agents in vitro and in vivo.
Wang HC; Lee AY; Chou WC; Wu CC; Tseng CN; Liu KY; Lin WL; Chang FR; Chuang DW; Hunyadi A; Wu YC
Mol Cancer Ther; 2012 Jul; 11(7):1443-53. PubMed ID: 22532598
[TBL] [Abstract][Full Text] [Related]
6. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.
Yao J; Huang A; Zheng X; Liu T; Lin Z; Zhang S; Yang Q; Zhang T; Ma H
J Cancer Res Clin Oncol; 2017 Mar; 143(3):419-431. PubMed ID: 27838786
[TBL] [Abstract][Full Text] [Related]
7. An ATM/TRIM37/NEMO Axis Counteracts Genotoxicity by Activating Nuclear-to-Cytoplasmic NF-κB Signaling.
Wu G; Song L; Zhu J; Hu Y; Cao L; Tan Z; Zhang S; Li Z; Li J
Cancer Res; 2018 Nov; 78(22):6399-6412. PubMed ID: 30254148
[TBL] [Abstract][Full Text] [Related]
8. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1.
Denchi EL; de Lange T
Nature; 2007 Aug; 448(7157):1068-71. PubMed ID: 17687332
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MALAT1 sensitizes liver cancer cells to 5-flurouracil by regulating apoptosis through IKKα/NF-κB pathway.
Ji DG; Guan LY; Luo X; Ma F; Yang B; Liu HY
Biochem Biophys Res Commun; 2018 Jun; 501(1):33-40. PubMed ID: 29702091
[TBL] [Abstract][Full Text] [Related]
10. Promotion of DNA repair by nuclear IKKβ phosphorylation of ATM in response to genotoxic stimuli.
Sakamoto K; Hikiba Y; Nakagawa H; Hirata Y; Hayakawa Y; Kinoshita H; Nakata W; Sakitani K; Takahashi R; Akanuma M; Kamata H; Maeda S
Oncogene; 2013 Apr; 32(14):1854-62. PubMed ID: 22614018
[TBL] [Abstract][Full Text] [Related]
11. Apigenin blocks IKKα activation and suppresses prostate cancer progression.
Shukla S; Kanwal R; Shankar E; Datt M; Chance MR; Fu P; MacLennan GT; Gupta S
Oncotarget; 2015 Oct; 6(31):31216-32. PubMed ID: 26435478
[TBL] [Abstract][Full Text] [Related]
12. Ikappa B kinase alpha involvement in the development of nasopharyngeal carcinoma through a NF-κB-independent and ERK-dependent pathway.
Xie Y; Li Y; Peng X; Henderson F; Deng L; Chen N
Oral Oncol; 2013 Dec; 49(12):1113-20. PubMed ID: 24075781
[TBL] [Abstract][Full Text] [Related]
13. Regulation and function of IKK and IKK-related kinases.
Häcker H; Karin M
Sci STKE; 2006 Oct; 2006(357):re13. PubMed ID: 17047224
[TBL] [Abstract][Full Text] [Related]
14. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response.
Golding SE; Rosenberg E; Neill S; Dent P; Povirk LF; Valerie K
Cancer Res; 2007 Feb; 67(3):1046-53. PubMed ID: 17283137
[TBL] [Abstract][Full Text] [Related]
15. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
17. Polo-like kinase 1 inhibits DNA damage response during mitosis.
Benada J; Burdová K; Lidak T; von Morgen P; Macurek L
Cell Cycle; 2015; 14(2):219-31. PubMed ID: 25607646
[TBL] [Abstract][Full Text] [Related]
18. Quercetin disrupts tyrosine-phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88 association, and inhibits MAPK/AP-1 and IKK/NF-κB-induced inflammatory mediators production in RAW 264.7 cells.
Endale M; Park SC; Kim S; Kim SH; Yang Y; Cho JY; Rhee MH
Immunobiology; 2013 Dec; 218(12):1452-67. PubMed ID: 23735482
[TBL] [Abstract][Full Text] [Related]
19. The IKKα-dependent non-canonical pathway of NF-κB activation is constitutively active and modulates progression-related functions in a subset of human melanomas.
Dewert N; Amschler K; Lorenz V; Schön MP
Arch Dermatol Res; 2016 Dec; 308(10):733-742. PubMed ID: 27744496
[TBL] [Abstract][Full Text] [Related]
20. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway.
Jiang L; Wang P; Sun YJ; Wu YJ
J Exp Clin Cancer Res; 2019 Jun; 38(1):265. PubMed ID: 31215501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
